BC
CORT icon

Bridgefront Capital’s Corcept Therapeutics CORT Stock Holding History

Bridgefront Capital’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-14,301
Closed -$310K – 489
2023
Q1 		$310K Buy
+14,301
New +$314K 0.19% 206

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Bridgefront Capital's CORT Position: Q2 2023 in Review

Bridgefront Capital sold out of Corcept Therapeutics (CORT) in Q2 2023, closing a stake of 14,301 shares — an estimated $310K sold.

Bridgefront Capital first reported a position in CORT in Q1 2023 and held it in 1 quarter. The position peaked at $310K in Q1 2023. 224 funds tracked by Wall St. Rank hold CORT as of Q2 2023.

  • Bridgefront Capital reported no remaining Corcept Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Bridgefront Capital sold 14,301 Corcept Therapeutics shares in Q2 2023, an estimated $310K.
  • Bridgefront Capital first reported a position in Corcept Therapeutics in Q1 2023 and held it in 1 quarter.
  • Bridgefront Capital's Corcept Therapeutics position peaked at $310K in Q1 2023.
  • 224 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2023.

Based on Bridgefront Capital's 13F filing for Q2 2023, filed 14 Aug 2023.